Patents by Inventor Dieter Kadereit

Dieter Kadereit has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200023070
    Abstract: The present invention relates to a conjugate or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon/GIP triple receptor agonist, a linker and a hyaluronic acid hydrogel bearing -L1-L2-L-Y-R2 groups, wherein Y represents an GLP-1/Glucagon/GIP triple receptor agonist moiety; and -L is a linker moiety—by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon/GIP triple receptor agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said conjugates as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon/GIP triple receptor agonist.
    Type: Application
    Filed: May 30, 2019
    Publication date: January 23, 2020
    Inventors: Dieter Kadereit, Thomas Olpp, Michael Walden, Nils Poth, Mandy Mohnicke, Michael Wagner, Pradeep Dhal
  • Patent number: 10538567
    Abstract: The present invention relates to trigonal GLP-1/glucagon/GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: January 21, 2020
    Assignee: SANOFI
    Inventors: Martin Bossart, Andreas Evers, Torsten Haack, Dieter Kadereit, Katrin Lorenz, Michael Wagner, Stefania Pfeiffer-Marek, Martin Lorenz
  • Patent number: 10519211
    Abstract: The present invention relates to trigonal GLP-1/glucagon/GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: December 31, 2019
    Assignee: SANOFI
    Inventors: Martin Bossart, Andreas Evers, Torsten Haack, Katrin Lorenz, Dieter Kadereit, Michael Wagner, Stefania Pfeiffer-Marek, Martin Lorenz
  • Publication number: 20180289822
    Abstract: The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon agonist linker conjugate Z-L1-L2-L-Y—R20, wherein Y represents an GLP-1/Glucagon agonist moiety; and -L is a linker moiety—by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said prodrugs as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon agonist.
    Type: Application
    Filed: June 2, 2016
    Publication date: October 11, 2018
    Inventors: Dieter KADEREIT, Michael WAGNER, Thomas OLPP, Nino MEYER, Pradeep DHAL, Paul KONOWICZ, Robert MILLER, James STEFANO, Magnus BESEV, Martin BOSSART, Katrin LORENZ, Torsten HAACK, Andreas EVERS
  • Publication number: 20180155407
    Abstract: The present invention relates to trigonal GLP-1/glucagon/GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Application
    Filed: December 1, 2017
    Publication date: June 7, 2018
    Inventors: Martin BOSSART, Andreas EVERS, Torsten HAACK, Katrin LORENZ, Dieter KADEREIT, Michael WAGNER, Stefania PFEIFFER-MAREK, Martin LORENZ
  • Publication number: 20180155406
    Abstract: The present invention relates to trigonal GLP-1/glucagon/GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Application
    Filed: December 1, 2017
    Publication date: June 7, 2018
    Inventors: Martin BOSSART, Andreas EVERS, Torsten HAACK, Dieter KADEREIT, Katrin LORENZ, Michael WAGNER, Stefania PFEIFFER-MAREK, Martin LORENZ
  • Publication number: 20180154005
    Abstract: The present invention relates to a conjugate or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon receptor agonist, a linker and a hyaluronic acid hydrogel bearing -L1-L2-L-Y—R20 groups, wherein Y represents an GLP-1/Glucagon receptor agonist moiety; and -L is a linker moiety—by formula (la), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon receptor agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said conjugates as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon receptor agonist.
    Type: Application
    Filed: December 1, 2017
    Publication date: June 7, 2018
    Inventors: Dieter KADEREIT, Michael WAGNER, Thomas OLPP, Nino MEYER, Martin BOSSART, Andreas EVERS, Peyman SAKHAII, Pradeep K. DHAL, Paul KONOWICZ, James E. STEFANO
  • Patent number: 9982029
    Abstract: The present invention relates to dual GLP-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: May 29, 2018
    Assignee: SANOFI
    Inventors: Martin Bossart, Andreas Evers, Torsten Haack, Katrin Lorenz, Dieter Kadereit, Michael Wagner, Bernd Henkel
  • Patent number: 9908868
    Abstract: The present invention relates to isoindolinone compounds. The isoindolinone compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of isoindolinone compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: March 6, 2018
    Assignee: SANOFI
    Inventors: Lothar Schwink, Christian Buning, Heiner Glombik, Matthias Gossel, Dieter Kadereit, Nis Halland, Matthias Lohmann, Christoph Pöverlein, Kurt Ritter
  • Patent number: 9896434
    Abstract: The present invention relates to indanone compounds. The indanone compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of indanone compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: February 20, 2018
    Assignee: SANOFI
    Inventors: Lothar Schwink, Christian Buning, Heiner Glombik, Matthias Gossel, Dieter Kadereit, Nis Halland, Matthias Lohmann, Christoph Pöverlein, Kurt Ritter
  • Patent number: 9789165
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: October 17, 2017
    Assignee: SANOFI
    Inventors: Dieter Kadereit, Katrin Lorenz, Andreas Evers, Torsten Haack, Michael Wagner, Bernd Henkel, Martin Lorenz, Siegfried Stengelin
  • Patent number: 9782411
    Abstract: {4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid or a pharmaceutically acceptable salt thereof for use in the prevention or treatment of AKI (acute kidney injury). Medicament and pharmaceutical composition thereof.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: October 10, 2017
    Assignee: SANOFI
    Inventors: Véronique Briand, Sabine Gratzer, Thomas Huebschle, Philip Janiak, Dieter Kadereit, Ashfaq Parkar, Bruno Poirier, Matthias Schaefer, Paulus Wohlfart
  • Patent number: 9758520
    Abstract: The present invention relates to substituted fused heterocyclic compounds. The substituted fused heterocyclic compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of substituted fused heterocyclic compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: September 12, 2017
    Assignee: SANOFI
    Inventors: Lothar Schwink, Christian Buning, Heiner Glombik, Matthias Gossel, Dieter Kadereit, Nis Halland, Matthias Lohmann, Christoph Pöverlein, Kurt Ritter
  • Patent number: 9758561
    Abstract: The present invention relates to dual GLP-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: September 12, 2017
    Assignee: SANOFI
    Inventors: Martin Bossart, Ralf Elvert, Andreas Evers, Torsten Haack, Siegfried Stengelin, Michael Wagner, Dieter Kadereit
  • Patent number: 9750788
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: September 5, 2017
    Assignee: SANOFI
    Inventors: Dieter Kadereit, Katrin Lorenz, Andreas Evers, Torsten Haack, Michael Wagner, Bernd Henkel, Martin Lorenz, Siegfried Stengelin
  • Patent number: 9751926
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: September 5, 2017
    Assignee: SANOFI
    Inventors: Dieter Kadereit, Katrin Lorenz, Andreas Evers, Torsten Haack, Michael Wagner, Bernd Henkel, Martin Lorenz, Siegfried Stengelin
  • Patent number: 9694053
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: July 4, 2017
    Assignee: SANOFI
    Inventors: Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Andreas Evers, Martin Bossart, Dieter Kadereit
  • Publication number: 20170029405
    Abstract: The present invention relates to indanone compounds. The indanone compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of indanone compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: April 2, 2015
    Publication date: February 2, 2017
    Inventors: Lothar SCHWINK, Christian BUNING, Heiner GLOMBIK, Matthias GOSSEL, Dieter KADEREIT, Nis HALLAND, Matthias LOHMANN, Christoph PÖVERLEIN, Kurt RITTER
  • Publication number: 20170022260
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake
    Type: Application
    Filed: December 12, 2014
    Publication date: January 26, 2017
    Inventors: Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Andreas Evers, Martin Bossart, Dieter Kadereit
  • Publication number: 20170022198
    Abstract: The present invention relates to substituted fused heterocyclic compounds. The substituted fused heterocyclic compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of substituted fused heterocyclic compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: October 3, 2016
    Publication date: January 26, 2017
    Inventors: Lothar SCHWINK, Christian BUNING, Heiner GLOMBIK, Matthias GOSSEL, Dieter KADEREIT, Nis HALLAND, Matthias LOHMANN, Christoph PÖVERLEIN, Kurt RITTER